DMD and rhabdomyosarcoma: We extracted skipping data that met the following criteria from the database to prepare our training and test datasets: (i) an absolute skipping efficacy was given by a numerical value; (ii) ASO concentration used in the experiment was given; (iii) rhabdomyosarcoma (RD) cells were used in the experiment to normalize experimental conditions; (iv) the skipping efficacy was not given as an EC50 value; (v) an ASO sequence that was sequential (not dual-targeting) in the pre-mRNA of dystrophin was used.